Zotepine in the treatment of acute hospitalized schizophrenic episodes.
The atypical antipsychotic zotepine was studied in an open, multicentre uncontrolled, post-marketing surveillance study in 108 schizophrenic patients hospitalized in 12 trial centres in Austria. Within the dosage range of 50-450 mg (mean at the end of the study, 207 +/- 125 mg/day), a significant reduction of positive as well as negative symptoms was noted. There was no increase in extrapyramidal side-effects during the study and a significant decrease in akathisia scores. The medication was well tolerated during the 42-day observation period. Zotepine improved both positive and negative symptoms and was not accompanied by extrapyramidal side-effects, justifying its classification as an atypical antipsychotic.
Kasper
S
S
Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Wien, Austria. sk@akh-wien.ac.at
Quiner
S
S
Barnas
C
C
Fabisch
H
H
Haushofer
M
M
Sackel
C
C
König
P
P
Lingg
A
A
Platz
T
T
Rittmannsberger
H
H
Stuppäck
C
C
Willeit
M
M
Zapotoczky
H G
HG
D000208:Acute Disease; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001317:Austria; D003988:Dibenzothiepins / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D011358:Product Surveillance, Postmarketing; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; C022172:zotepine